A Decade of SG&A: Zoetis Inc. vs. Summit Therapeutics Inc.

In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is key. Over the past decade, Zoetis Inc. and Summit Therapeutics Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses.

Zoetis Inc.: A Steady Climb

From 2014 to 2023, Zoetis Inc. has consistently increased its SG&A expenses, peaking at approximately $2.15 billion in 2023. This represents a 31% rise from 2014, reflecting the company's strategic investments in growth and market expansion.

Summit Therapeutics Inc.: A Different Path

Conversely, Summit Therapeutics Inc. has seen a more volatile trajectory. Starting at $6.8 million in 2014, their SG&A expenses surged by over 300% to reach $28.2 million in 2023. This dramatic increase highlights Summit's aggressive push towards innovation and development.

These trends underscore the diverse approaches companies take in navigating the competitive pharmaceutical sector.